1.
ClinicalTrials.gov; 18/03/2022; TrialID: NCT05298800
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05298800
RESUMO
Condition:
Safety;Immunogenicity, Vaccine;COVID-19 Vaccines;Influenza Vaccines;Pneumococcal VaccinesIntervention:
Biological: VaccinePrimary outcome:
Seroconversion rate of neutralizing antibodyCriteria:
Inclusion Criteria:
- Healthy adults 18 years old and older
- Over 6 months after primary immunization with COVID-19 vaccines
- Can understand and sign the consent
- Can provide effective personal identification
Exclusion Criteria:
- Has a history of COVID-19 infection
- Less than 6 months after primary immunization with COVID-19 vaccines
- Already vaccinated with influenza vaccines of that year
- Vaccinated with pneumococcal vaccines within 5 years
- Has a history of severe hypersensitivity reaction to vaccines
- Has uncontrolled seizure or other severe neural system illnesses
- Has a fever, chronic disease, or acute disease during immunization
- Gestation period, lactation period, or planning to get pregnant within 3 months
- Administrated with other drugs under research within 30 days before vaccination
- Received attenuated vaccines within 14 days before vaccination
- Received subunit vaccines or inactivated vaccines within 7 days before vaccination
- Other conditions based on researcher's judgement
2.
ClinicalTrials.gov; 19/10/2021; TrialID: NCT05087277
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05087277
RESUMO
Condition:
COVID-19Primary outcome:
Neutralizing capabilities to variant COVID-19 after primary and booster vaccination;Titer of Subclass of IgG after primary and booster vaccinationCriteria:
Inclusion Criteria:
- Between the ages of 18 and 59
- Healthy
- No vaccination with COVID-19 before become participant
- Agreed to take a blood sample
Exclusion Criteria:
- who cannot take the COVID-19 vaccine due to some personal reasons
- history of SARS-CoV, SARS-CoV-2, or Middle East respiratory syndrome infection
- high-risk epidemiology history within 14 days before enrolment (eg, travel or
residence history in communities with case reports, or contact history with someone
infected with SARS-CoV-2)
- axillary temperature of more than 37·0?
- history of allergy to any vaccine component.
3.
ClinicalTrials.gov; 29/09/2021; TrialID: NCT05072496
Clinical Trial Register
| ICTRP | ID: ictrp-NCT05072496
RESUMO
Condition:
COVID-19Primary outcome:
Durability of humoral and cellular immune responsesCriteria:
Inclusion Criteria:
- Working at the CDC
- Between the ages of 18 and 59
- Healthy
- Not vaccinated with COVID-19 vaccine
- Agreed to take a blood sample
Exclusion Criteria:
- who cannot take the COVID-19 vaccine due to some personal reasons
- history of SARS-CoV, SARS-CoV-2, or Middle East respiratory syndrome infection
- high-risk epidemiology history within 14 days before enrolment (eg, travel or
residence history in communities with case reports, or contact history with someone
infected with SARS-CoV-2)
- axillary temperature of more than 37·0?
- history of allergy to any vaccine component.